Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harish Dhingra

Adolescent Medicine Bedford, TX Medical Doctor

NPI 1710931530 CMS profile 77298

1200 Circle Ln, Bedford, TX 76022

Open in the dashboard

General payments

$2,957

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harish Dhingra of Bedford, TX is reported in the CMS Open Payments database as having received $2,957 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273 7
2024 General $664 28
2023 General $319 6
2022 General $296 13
2021 General $92 6
2020 General $63 5
2019 General $1,251 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harish Dhingra
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Harish Dhingra were reported at $273. Among 113 Adolescent Medicine profiles paid that year, the median was $165 and the middle half received between $61 and $402.

Show as a table
Year Harish Dhingra Adolescent Medicine median Middle half National median
2019 $1,251 $151 $36–$708 $163
2020 $63 $123 $24–$337 $114
2021 $92 $155 $54–$620 $132
2022 $296 $158 $50–$556 $149
2023 $319 $170 $52–$612 $160
2024 $664 $182 $65–$431 $164
2025 $273 $165 $61–$402 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $499 7 payments
  2. Otsuka America Pharmaceutical, Inc. $374 5 payments
  3. Allergan Inc. $315 3 payments
  4. Abbott Laboratories $263 12 payments
  5. Novo Nordisk Inc $246 11 payments
  6. E.R. Squibb & Sons, L.L.C. $135 1 payment
  7. Sunovion Pharmaceuticals Inc. $128 3 payments
  8. Neurocrine Biosciences, Inc. $96 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $91 5 payments
  10. Astellas Pharma US Inc $87 5 payments
  11. Other $723 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,957 92 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $315 3 payments
  2. AUSTEDO $272 5 payments
  3. FreeStyle Libre 3 $263 12 payments
  4. Austedo XR $227 2 payments
  5. ABILIFY MAINTENA $224 2 payments
  6. Ozempic $194 7 payments
  7. REXULTI $150 3 payments
  8. COBENFY $135 1 payment
  9. ABILIFY ASIMTUFII $125 1 payment
  10. INGREZZA $96 1 payment
  11. Other $1,346 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

154

Median for Internal Medicine: 777

Drug cost

$1,596

Median for Internal Medicine: $73,373

Branded share of claims

28.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $648
Atorvastatin Calcium Generic 26 $281
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 21 $215
Tramadol Hcl Generic 11 $170
Escitalopram Oxalate Generic 11 $75
Amlodipine Besylate Generic 21 $56
Montelukast Sodium Generic 13 $56
Rosuvastatin Calcium Generic 11 $50
Lisinopril Generic 17 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $112
$112 — —
CAPLYTA
  • ITI, Inc. $54
$54 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $54
$54 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $32
  • Lundbeck LLC $14
$46 — —
RYBELSUS
  • Novo Nordisk Inc $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record